ABSTRACT Introduction: The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with ALK receptor tyrosine kinase gene (ALK)-positive advanced nonsquamous NSCLC. This result was consistent with that in the smaller subset of East Asian patients in PROFILE 1014. The subsequent study reported here prospectively evaluated crizotinib in a larger East Asian patient population.
ABSTRACT Introduction: The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in previously untreated patients with ALK receptor tyrosine kinase gene (ALK)-positive advanced nonsquamous NSCLC. This result was consistent with that in the smaller subset of East Asian patients in PROFILE 1014. The subsequent study reported here prospectively evaluated crizotinib in a larger East Asian patient population.
Methods:
In this open-label phase III study (PROFILE 1029), patients were randomized 1:1 to receive orally administered crizotinib 250 mg twice daily continuously (3-week cycles) or intravenously administered chemotherapy (pemetrexed 500 mg/m 2 , plus cisplatin 75 mg/m 2 , or carboplatin [at a dose to produce area under the concentration-time curve of 5-6 mg$min/mL]) every 3 weeks for a maximum of six cycles. PFS confirmed by independent radiology review was the primary end point.
Results: Crizotinib significantly prolonged PFS (hazard ratio, 0.402; 95% confidence interval [CI] : 0.286-0.565; p < 0.001). The median PFS was 11.1 months with crizotinib and 6.8 months with chemotherapy. The objective response rate was 87.5% (95% CI: 79.6-93.2%) with crizotinib versus 45.6% (95% CI: 35.8-55.7%) with chemotherapy (p < 0.001). The most common adverse events were increased transaminase levels, diarrhea, and vision disorders with crizotinib and leukopenia, neutropenia, and anemia with chemotherapy. Significantly greater improvements from baseline in patient-reported outcomes were seen in crizotinib-treated versus chemotherapy-treated patients.
Conclusions: First-line crizotinib significantly improved PFS, objective response rate, and patient-reported outcomes compared with standard platinum-based chemotherapy in East Asian patients with ALK-positive advanced NSCLC, which is similar to the results from PROFILE 1014. The safety profiles of crizotinib and chemotherapy were consistent with those previously published.
Introduction
Rearrangements of the ALK receptor tyrosine kinase (ALK) gene occur in approximately 3% to 5% of patients with NSCLC, 1, 2 although prevalence may vary between populations. 3 The frequency of ALK gene rearrangements appears to be similar among East Asian and non-Asian patients. 4 Crizotinib, a potent inhibitor of ALK, mesenchymalepithelial transition, and ROS1 receptor tyrosine kinases, 5, 6 has shown superior progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) in quality of life (QOL) compared with firstline platinum-based chemotherapy in a global study (PRO-FILE 1014) of patients with ALK-positive advanced nonsquamous NSCLC, 7 as well as in second-line therapy (PROFILE 1007), among patients who received prior treatment with platinum-based chemotherapy. 8 The primary objective of this phase III study (PRO-FILE 1029) conducted among East Asian patients with ALK-positive advanced NSCLC was to determine the effect of first-line treatment with crizotinib or platinumbased chemotherapy on PFS. It was also of interest to determine whether the results observed in a subset of East Asian patients from the earlier PROFILE 1014 study would be confirmed by this study.
Materials and Methods

Patients
The inclusion criteria included histologically or cytologically confirmed locally advanced, recurrent, or metastatic nonsquamous NSCLC positive for an ALK rearrangement, as determined centrally by a Vysis ALK Break Apart FISH assay (Abbott Molecular, Abbott Park, IL); no previous systemic treatment for advanced disease; female or male sex and age 18 to 70 years; measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 9 ; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2; and adequate hepatic, renal, and bone marrow function. Patients with brain metastases were eligible if appropriately treated and neurologically stable for at least 2 weeks before enrollment.
All patients provided written informed consent before enrollment. The institutional review board or independent ethics committee at each participating center approved the protocol, which complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects, Good Clinical Practice guidelines, the Declaration of Helsinki, and local laws.
Study Design and Treatment
This is an ongoing open-label, multicenter, randomized, phase III study (PROFILE 1029, ClinicalTrials.gov identifier NCT01639001). Patients were randomized 1:1 to receive orally administered crizotinib 250 mg twice daily or intravenously administered platinumbased chemotherapy (pemetrexed 500 mg/m 2 , plus cisplatin 75 mg/m 2 , or carboplatin [at a dose to produce an area under the concentration-time curve of 5-6 mg$min/mL]) every 3 weeks for a maximum of six cycles. The investigator made the choice of platinum-based chemotherapy.
Randomization was stratified according to ECOG PS (0-1 versus 2). Treatment continued until RECISTdefined disease progression, development of unacceptable toxicity, withdrawal of consent, or death. Patients were permitted to continue chemotherapy (for a maximum of six cycles) or crizotinib treatment as assigned beyond the time of RECIST-defined disease progression, as determined by independent radiology review (IRR), at the discretion of the investigator if the patient was perceived to be experiencing clinical benefit. Patients in the chemotherapy arm who had disease progression, as confirmed by IRR, could cross over to the crizotinib arm if they met the safety screening criteria.
The primary end point was PFS (time from randomization to RECIST-defined progression, as assessed by IRR, or death). Secondary end points included ORR (percentage of patients with a complete or partial response according to RECIST, as assessed by IRR), overall survival (OS), safety, and PROs.
Assessments
Tumor assessments were performed at screening and every 6 weeks during treatment until RECISTdefined progression, as assessed by IRR. Brain (intracranial) or bone lesions detected at screening were evaluated every 6 weeks; otherwise, the brain was evaluated when clinically indicated. Bone scans were repeated every 12 weeks only if bone metastases were present at baseline; otherwise, a repeat bone scan was required only if new bone metastases were suspected. If bone metastases outside of the chest, abdomen, or pelvis were identified by IRR during screening, computed tomography/magnetic resonance imaging scans of the extremities were required every 6 weeks in addition to the bone scans every 12 weeks. All scans underwent IRR by radiologists blinded to treatment assignment. Adverse events (AEs) were classified and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. PROs were assessed by using the European Organization for Research and Treatment of Cancer Quality-of-Life Core Questionnaire (QLQ-C30), 10,11 the corresponding Lung Cancer Module (QLQ-LC13), 12 and the 3-Level EuroQol Group 5-Dimension Self-Report Questionnaire (EQ-5D-3L). 13 
Statistical Analysis
The study was designed to detect an improvement in median PFS from 6.4 to 10 months with 80% power and a one-sided significance level of 0.025, with a total of 181 patients (160 PFS events) required. To account for potential discordance between investigators and IRR, it was planned that 200 patients would be enrolled.
Efficacy end points were summarized by treatment arm in the intention-to-treat population, which was defined as all randomized patients. The Kaplan-Meier method was used to estimate time-to-event end points. Differences in PFS and OS between treatment arms were analyzed by a one-sided log-rank test stratified for randomization (ECOG PS 0-1 versus 2) and two additional important covariates (brain metastases [presence versus absence] and ethnicity [Han Chinese versus other]). A Cox regression model stratified for the aforementioned factors was fitted, and estimated hazard ratios (HRs) were provided. Differences between treatment arms in time to progression (TTP) (for all patients and by brain metastases at baseline) were analyzed by a one-sided unstratified log-rank test. ORR and disease control rate at 12 weeks were analyzed by a two-sided Pearson chi-square test.
Descriptive statistics were used to summarize patient characteristics, patient disposition, treatment duration, and safety. Time to deterioration (TTD) was the time from randomization to the earliest demonstration of at least a 10-point increase after baseline in the patient's QLQ-LC13 score in any of three lung cancer-associated symptoms (pain in the chest, dyspnea, or cough). Additional details of the statistical methods are provided in Supplementary Data 1.
Results
Patients
Between September 2012 and July 2014, patients with previously untreated ALK-positive advanced NSCLC were enrolled at 35 centers in China, Hong Kong, Malaysia, the Republic of China, and Thailand. Overall, 207 patients were randomized to treatment with either crizotinib (n ¼ 104) or chemotherapy (n ¼ 103) (with 34 of those 103 patients [33%] receiving pemetrexed plus cisplatin, 67 [65%] receiving pemetrexed plus carboplatin, and two randomized to chemotherapy but not treated) and constituted the intention-to-treat population ( Supplementary Fig. 1 ). Data for this report are from visits through June 30, 2015.
Demographics and baseline characteristics were comparable between both arms (Table 1) .
Efficacy
A total of 166 patients (77 treated with crizotinib and 89 treated with chemotherapy) experienced PFS events. The HR (crizotinib versus chemotherapy) was 0.402 (95% confidence interval [CI]: 0.286-0.565, two-sided p < 0.001) ( Table 2 and Fig. 1A ). The median PFS was 11.1 months (95% CI: 8.3-12.6) with crizotinib and 6.8 months (95% CI: 5.7-7.0) with chemotherapy. Most subgroup analyses of baseline patient demographics and disease characteristics indicated significant improvement in PFS with crizotinib (Fig. 1B) .
The ORR was statistically significantly (two-sided p < 0.001) higher with crizotinib (87.5% [95% CI: 79.6-93.2%]) than with chemotherapy (45.6% [95% CI: 35.8-55.7%]) (see Table 2 ). The median times to response were 6.3 weeks (range 5.1-24.9) and 12.1 weeks (range 5.7-36.1) with crizotinib and chemotherapy, respectively. Duration of response was 10.2 months (95% CI: 8.2-13.8) with crizotinib and 4.2 months (95% CI: 3.8-4.6) with chemotherapy (see Table 2 ). Figure 2 shows the best percentage change from baseline in target lesions and the best overall response for individual patients. The disease control rate at week 12 was 82.7% (95% CI: 74.0-89.4%) with crizotinib and 73.8% (95% CI: 64.2-82.0%) with chemotherapy (see Table 2 ).
The median durations of follow-up for OS were 22.5 months (95% CI: 20.5-23.3) and 21.6 months (95% CI: 20.7-23.0) with crizotinib and chemotherapy, respectively. Among the 104 and 103 patients randomized to receive crizotinib and chemotherapy, respectively, 35 (33.7%) and 37 (35.9%) died. The HR was 0.897 (95% CI: 0.556-1.445, one-sided p ¼ 0.33) (see Table 2 and Fig. 1B) . The median OS times were 28.5 months (95% CI: 26.4-not reached) with crizotinib and 27.7 months (95% CI: 23.9-not reached) with chemotherapy ( Supplementary  Fig. 2 ). A total of 83 patients (80.6%) from the chemotherapy arm crossed over and received subsequent crizotinib treatment.
TTP
Safety
The median durations of treatment (see Supplementary Data 1 for definition) were 15.6 months (range 1.1-28.7) and 4.2 months (range 0.7-5.6) for crizotinib-and chemotherapy-treated patients, respectively, with a maximum of six cycles permitted. Table 3 shows the all-causality AEs reported in at least 15% of patients in either treatment arm. Increased transaminase levels, vision disorder, and diarrhea occurred more frequently (5% absolute difference between arms) with crizotinib. Anemia, leukopenia, and neutropenia were more frequent with chemotherapy. The all-causality grade 3 or 4 AEs reported in at least 2% of patients in either treatment arm are presented in Supplementary Table 1 . The most commonly reported grade 3 all-causality AEs occurring in at least 5% of patients were neutropenia (16.3%) and increased transaminase levels (11.5%) with crizotinib and neutropenia (20.8%), anemia (11.9%), leukopenia (9.9%), and thrombocytopenia (5.9%) with chemotherapy. The most commonly reported grade 4 all-causality AEs were dyspnea (1.9%) for crizotinib-treated patients and neutropenia (4.0%) and thrombocytopenia (4.0%) for chemotherapy-treated patients. Two grade 5 AEs (death of unknown cause and interstitial lung disease) were assessed as being related to crizotinib treatment. Permanent discontinuation of crizotinib was associated with AEs in 19 patients (18.3%), with AEs in three of those patients (anemia, death, and interstitial lung disease) assessed as treatment related. In the chemotherapy arm, there were four permanent treatment discontinuations (4.0%) associated with AEs, with one of these (hypersensitivity) assessed as related to treatment. 
PROs
Supplementary Table 2 summarizes the changes from baseline in scores for QOL functioning, symptoms, and general health status on the QLQ-C30, QLQ-LC13, and EQ-5D-3L. Improvements from baseline were observed in overall global QOL for crizotinib-treated patients but not for chemotherapy-treated patients, with the difference being statistically significant (p < 0.001) in favor of crizotinib. Domains on the QLQ-C30 with statistically significantly greater improvements or less deterioration (p < 0.05) were physical functioning, role functioning, social functioning, and cognitive functioning. A statistically significantly (p < 0.05) greater improvement from baseline was also observed in general health status scores with crizotinib versus with chemotherapy, as assessed by the EQ-5D-3L visual analog scale.
There were significantly greater overall reductions from baseline with crizotinib than with chemotherapy in symptoms of fatigue, pain, insomnia, appetite loss, alopecia, pain in the arm/shoulder, pain in other body parts, coughing, dyspnea, and pain in the chest. Crizotinib-treated patients had a significantly greater delay in TTD in the composite end point of lung cancer symptoms of pain in the chest, cough, or dyspnea (HR ¼ 0.432, 95% CI: 0.307-0.610, p < 0.001). The median TTD was 2.8 months (95% CI: 1.4-6.9) for crizotinib-treated patients versus 0.3 months (95% CI: 0.3-0.5) for chemotherapy-treated patients (Fig. 1C) .
Discussion
PROFILE 1029 is the first comparative study of crizotinib versus platinum-based chemotherapy in Log-rank test (standardized) stratified by ECOG PS, brain metastases, ethnicity, and one-sided p value from the log-rank test.
e One-sided p value from the log-rank test stratified by ECOG PS, brain metastases, and ethnicity.
f Estimated by using the Kaplan-Meier curve.
g Calculated by using the normal approximation to the log-transformed cumulative hazard rate.
h Based on independent radiology review.
i Determined by using the exact method based on F distribution. East Asian patients with ALK-positive advanced NSCLC and provides confirmation of the results seen in the smaller subset of East Asian patients who participated in PROFILE 1014. Crizotinib improved PFS independent of age, sex, ECOG PS, tumor histological type, and type of platinum-based chemotherapy. ORR was also statistically significantly higher with crizotinib than with chemotherapy. Although the HR for OS favored crizotinib, it did not reach statistical significance, most likely because of the low percentage of deaths across both treatment arms (35.1%) and the high rate of patients in the chemotherapy arm who subsequently received crizotinib treatment (80.6%). Among patients with brain metastases at baseline, an improvement in PFS was observed in those who were randomized to crizotinib versus in those randomized to chemotherapy. A potential reduction in risk of intracranial disease progression was also noted, 14 and statistically significantly (p < 0.05) greater improvements from baseline in a range of PROs were observed among the crizotinib-versus chemotherapy-treated patients.
Findings from this study reflect the positive results seen in PROFILE 1014, 7 which showed that the HR for PFS with crizotinib was 0.45 (95% CI: 0.35-0.60, p < 0.001) and favored crizotinib across most subgroups defined according to stratification factors and other baseline characteristics, including race. Among Asian patients (n ¼ 157) in PROFILE 1014, PFS was significantly longer with crizotinib versus with chemotherapy (HR ¼ 0.44, 95% CI: 0.30-0.65, p < 0.001; median 13.6 and 7.0 months, respectively) and ORR was significantly (p < 0.001) higher with crizotinib (70% versus 54% for chemotherapy). 15 There was also no significant difference in OS between treatment arms in PROFILE 1014, most likely because of the low death rate (26%) at the time of analysis and because 70% of chemotherapy-treated patients subsequently received crizotinib. Both studies showed significantly greater overall improvements from baseline in key PROs with crizotinib versus with chemotherapy.
Overall, the crizotinib and chemotherapy safety profiles observed in PROFILE 1029 were also consistent with those from both PROFILE 1014 and PROFILE 1007. 7, 8 The 18.3% rate of permanent AErelated discontinuation with crizotinib was higher than the 4.0% rate of permanent AE-related discontinuation with chemotherapy, which was likely due in part to the more than fourfold longer median duration of treatment in the crizotinib arm. Of note, crizotinibtreated patients could be treated with crizotinib beyond progression and could potentially be more prone to AEs as a result of experiencing additional disease-associated morbidity.
The efficacy, safety, and PRO results observed in both PROFILE 1014 and PROFILE 1029 were comparable. These findings indicate that Asian ethnicity should not influence clinical decisions regarding the use of crizotinib. 16 Neither PROFILE 1014 nor PROFILE 1029 included continuation of pemetrexed beyond the planned six cycles because both studies were designed and initiated before maintenance pemetrexed was established as a standard of care. Nevertheless, when maintenance pemetrexed was used in a recent study of patients with ALK-positive NSCLC, the median PFS was 8.1 months with chemotherapy, which is slightly longer 17 than the median PFS of 6.8 months for chemotherapy in PROFILE 1029, in which maintenance therapy was not permitted. Thus, if maintenance pemetrexed therapy had been used in PROFILE 1029, it would likely have had only a minimal impact on the PFS end point.
In conclusion, in East Asian patients with ALKpositive advanced NSCLC, crizotinib demonstrated significantly improved PFS, ORR, and PROs and had a distinct safety profile that was tolerable and manageable. PROFILE 1029 confirmed the results observed in the subset of Asian patients in PROFILE 1014. Therefore, the consistency between results of PROFILE 1014 and PROFILE 1029 has the potential to validate an approach of using findings from subset populations of interest in well-designed prospective studies, without having to perform a conventional large phase III confirmatory study of a particular subset population for targeted therapies. Adverse events are listed here if they were reported in at least 15% of patients in either treatment arm; rates were not adjusted for differences in treatment duration (median, 15.6 months for crizotinib and 4.2 weeks for chemotherapy). Frequency categories were based on the incidence of adverse events of any grade. a Includes only events before crossover to crizotinib.
b Two patients were randomized but did not receive treatment. 
